STAT3 and ovarian carcinoma: Likewise, parallel p-STAT3 and total STAT3 upregulation was observed in Paclitaxel and Cisplatin-resistant ovarian cancer cell lines (14, 16), suggesting that elevated and prolonged STAT3 activation increases its own expression in drug-resistant cell lines.